Insider Transactions in Q3 2024 at Mineralys Therapeutics, Inc. (MLYS)
Insider Transaction List (Q3 2024)
Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Sep 12
2024
|
David Malcom Rodman Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,349
+4.81%
|
$6,349
$1.08 P/Share
|
Sep 11
2024
|
David Malcom Rodman Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,018
+4.04%
|
$0
$0.54 P/Share
|
Aug 12
2024
|
David Malcom Rodman Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
11,365
+4.85%
|
$0
$0.81 P/Share
|
Jul 24
2024
|
Brian Taylor Slingsby Director |
SELL
Open market or private sale
|
Indirect |
550,000
-5.98%
|
$7,150,000
$13.05 P/Share
|
Jul 16
2024
|
David Malcom Rodman Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
525
-0.51%
|
$7,875
$15.0 P/Share
|
Jul 16
2024
|
David Malcom Rodman Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
525
+0.51%
|
$525
$1.08 P/Share
|
Jul 12
2024
|
David Malcom Rodman Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,349
+5.81%
|
$6,349
$1.08 P/Share
|
Jul 11
2024
|
Jon Congleton Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
15,746
-1.7%
|
$204,698
$13.34 P/Share
|
Jul 11
2024
|
Adam Scott Levy CFO and Secretary |
SELL
Open market or private sale
|
Direct |
10,757
-4.16%
|
$139,841
$13.14 P/Share
|
Jul 11
2024
|
David Malcom Rodman Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,017
+4.94%
|
$0
$0.54 P/Share
|